Shares of Beam Therapeutics Inc. ( NASDAQ:BEAM – Get Free Report ) have been given a consensus rating of 'Moderate Buy' by the ten research firms that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $63.82. Several brokerages have recently commented on BEAM.

https://www.dailypolitical.com/2023/09/09/beam-therapeutics-inc-nasdaqbeam-receives-63-82-consensus-price-target-from-analysts.html

#dailypolitical